Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Solid tumor
ECOG performance status 0-2
Life expectancy greater than or equal to 12 weeks
Must meet certain blood laboratory values
Must meet criteria for time since the last dose of prior therapy
Must provide written informed consent to participate in this study
You may not be if
Active and/or symptomatic brain tumors or brain metastases.
Patients with unresolved nausea, vomiting, or diarrhea
Any ongoing severe and/or uncontrolled medical condition that could compromise participation in the study including heart, lung or inflammatory disease
Any disease that may significantly alter the absorption of the study drug (for example, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or removal of small bowel)
Patients who are currently receiving treatment with steroids at a certain dose or other immunosuppressive treatment that cannot be stopped prior to starting study drug
Patients who are currently receiving treatment with certain medications
Patients who have received radiation therapy or have undergone major surgery within the last 4 weeks
Women of child-bearing potential who are pregnant or breast feeding.
Known diagnosis of human immunodeficiency virus (HIV) infection or chronic active hepatitis B or C
Patients unwilling or unable to follow the protocol
